Relationships between SOC loss and erosion intensity in (a) events of silty clay loam and (b) events of silty loam.

<p>Relationships between SOC loss and erosion intensity in (a) events of silty clay loam and (b) events of silty loam.</p

Correlation analysis between ERoc and different size particles.

<p>Correlation analysis between ERoc and different size particles.</p

Temporal variations of SOC loss rate for different rainfall events.

<p>The error bars denote the standard deviations. Silty clay loam-90 and Silty clay loam-120 (Silty loam-90 and Silty loam-120) denote the rainfall events of Silty clay loam (Silty loam) soil with rainfall intensities of 90 mm h^-1 and 120 mm h^-1.</p

Characteristics of the study soils.

<p>Characteristics of the study soils.</p

Enrichment ratio of organic carbon (ERoc) in sediment for different rainfall events.

<p>The error bars denote the standard deviations. Silty clay loam and Silty loam represent the soils, 90 and 120 represent the rainfall intensities (mm h^-1).</p

Summary parameters for each rainfall experiment.

<p>Summary parameters for each rainfall experiment.</p

Temporal variations in the percentage of ultimate sediment particles under different rainfall events.

<p>Silty clay loam and Silty loam represent the soils, 90 and 120 represent the rainfall intensities (mm h^-1), and 10, 15, 20 and 25 represent the slope gradient (°).</p

Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors

<div><p>Chromogranin A (CgA), present in the chromaffin granules of neuroendocrine cells, is a useful biomarker for the diagnosis of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This study was conducted to investigate the potential role of circulating CgA in monitoring clinical response in Chinese patients with advanced GEP-NETs. Eighty patients with advanced GEP-NETs treated in Peking University Cancer Hospital from September 2011 to May 2014 and 65 healthy individuals were included in this study. Serum CgA levels were analyzed for relationship with patient’s baseline characteristics and clinical outcome. Median CgA levels were significantly higher in patients with advanced GEP-NETs than in healthy individuals (93.8 ng/mL vs. 37.1 ng/mL; P<0.01), as well as significantly higher in patients with carcinoid syndrome or liver metastasis than in those without carcinoid syndrome (298.8 ng/mL vs. 82.9 ng/mL; P = 0.011) or liver metastasis (137.0 ng/mL vs. 64.4 ng/mL; P = 0.023). A CgA cutoff value of 46.2 ng/mL was used in this study with a sensitivity of 78.8% and specificity of 73.8%. Patients with CgA levels higher than 46.2 ng/mL had a worse prognosis than patients with CgA levels lower than 46.2 ng/mL (P = 0.045). Notably, a weak correlation was observed between changes in serum CgA levels and clinical response to the IP regimen as well as SSAs. Our data also indicate that serum CgA could be a useful indicator of patient prognosis though there is more research required in order to validate such claims.</p></div

Clinicopathologic features of colorectal adenocarcinomas stratified by signet-ring cell component.

<p>Clinicopathologic features of colorectal adenocarcinomas stratified by signet-ring cell component.</p

Multigene Mutation Profiling by NGS.

<p>Multigene Mutation Profiling by NGS.</p